Ye Weiguo sold $21K of GYRE
Ye Weiguo (Chief Operating Officer) sold 3,500 shares of GYRE THERAPEUTICS, INC. (GYRE) at $6.08 on 2026-05-22.
How this was made
The 30-second read
Why it matters
This type of disclosure can slightly affect sentiment, but without additional company-specific catalysts (trial results, guidance, financing, partnerships) it typically has limited predictive power.
Market read
Traders may monitor for clustering of insider sales or changes in insider buying/selling patterns, but this single transaction is unlikely to drive a sustained repricing alone.
What to watch
Absence of a stated 10b5-1 plan may increase speculation; confirm whether other insiders filed similar sales/buys around the same dates.
Background
The article is an SEC Form 4 insider transaction disclosure for GYRE Therapeutics, filed via EDGAR.
Ticker impact
SEC Form 4 shows COO Ye Weiguo sold 3,500 shares of GYRE in an open-market transaction on 2026-05-22.
Likely limited immediate impact; watch for follow-on insider activity or corroborating company news.
The sale is disclosed as an open-market transaction with no 10b5-1 plan indicated, but the article provides only a small absolute value and no accompanying operational/clinical catalyst.
Market effects
No direct sector read-across provided; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
The sale could be routine liquidity management rather than a bearish view, especially since holdings remain large after the transaction.
Key entities
- insiderYe Weiguo
Chief Operating Officer who sold 3,500 shares of GYRE on 2026-05-22.
- issuerGYRE Therapeutics, Inc.
Company whose shares were sold by an officer; ticker GYRE.